Patient Square Capital LP Has $7.64 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Patient Square Capital LP cut its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 104,262 shares of the company’s stock after selling 9,200 shares during the quarter. Mirum Pharmaceuticals accounts for approximately 2.0% of Patient Square Capital LP’s investment portfolio, making the stock its 10th biggest holding. Patient Square Capital LP’s holdings in Mirum Pharmaceuticals were worth $7,643,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Emerald Advisers LLC raised its holdings in Mirum Pharmaceuticals by 20.9% in the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $808,000. Candriam S.C.A. increased its holdings in shares of Mirum Pharmaceuticals by 8.0% in the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after purchasing an additional 30,021 shares in the last quarter. Baader Bank Aktiengesellschaft purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth $503,000. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth $22,041,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MIRM shares. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $110.17.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,631 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $271,782.30. Following the completion of the sale, the chief operating officer owned 20,655 shares of the company’s stock, valued at approximately $2,133,661.50. The trade was a 11.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 9,108 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,136 shares of company stock worth $4,352,029 over the last three months. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Stock Down 0.3%

Shares of MIRM stock opened at $105.16 on Monday. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $107.41. The stock has a market cap of $5.40 billion, a P/E ratio of -122.28 and a beta of 0.49. The company has a 50 day simple moving average of $90.24 and a two-hundred day simple moving average of $77.94.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.